12 January 2021 - Deborah Wilkes
Procter & Gamble (P&G) has abandoned its proposed acquisition of Billie, AFT Pharmaceuticals’ Maxigesic pain reliever has been launched in Canada as Combogesic, and Sanofi has revealed the name and chief of its proposed active pharmaceutical ingredients (API) company.
P&G abandons Billie deal
Procter & Gamble (P&G) has abandoned its proposed acquisition of Billie, the US female body care company offering razors, shaving cream, body wash and body lotion.
P&G’s announcement came soon after the US Federal Trade Commission (FTC) challenged the deal because it “would have eliminated dynamic competition from Billie”.
On 8 December 2020, the FTC filed an administrative complaint and authorised a suit in federal court to block the deal.
The acquisition was announced in January 2020 (click here to read the News story).
AFT’s Maxigesic launched in Canada
AFT Pharmaceuticals said BioSyent had now launched its Maxigesic combination analgesic in Canada as a non-prescription medicine under the Combogesic brand name.
BioSyent said Combogesic was the first fixed-dose combination of paracetamol and ibuprofen in a single tablet in Canada.
In Canada, each Combogesic tablet contains 325mg paracetamol and 97.5mg ibuprofen.
AFT announced in 2019 that Health Canada had approved the tablet form of Combogesic (click here to read the News story).
The New Zealand company said the Canadian launch was its “first foray into North America”.
Sanofi provides update on API company
Sanofi has revealed that its proposed European active pharmaceutical ingredients (API) company will be named EUROAPI and will led by Karl Rotthier as chief executive officer.
The French pharmaceutical company announced in February 2020 that it planned to create a standalone European API supplier by combining its API commercial and development activities with six of its European API production sites (click here to read the News story).
Rotthier will be future chief executive officer of EUROAPI with effect from 18 January 2021. His most recent position was chief executive officer of Centrient Pharmaceuticals.
Sanofi said it expected to take a decision on the Initial Public Offering (IPO) to separate the business in 2022.
EUROAPI would be the largest API player in the European Union, noted Sanofi, with expected 2022 sales of approximately EUR1 billion (USD1.2 billion).